Biora Therapeutics, Inc.

Report azionario OTCPK:BIOR.Q

Capitalizzazione di mercato: US$597.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biora Therapeutics Gestione

Criteri Gestione verificati 3/4

Biora Therapeutics Il CEO è Adi Mohanty, nominato in Nov2021, e ha un mandato di 3.5 anni. la retribuzione annua totale è $ 3.14M, composta da 18.3% di stipendio e 81.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.52% delle azioni della società, per un valore di $ 3.10K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 3.9 anni.

Informazioni chiave

Adi Mohanty

Amministratore delegato

US$3.1m

Compenso totale

Percentuale dello stipendio del CEO18.29%
Mandato del CEO3.5yrs
Proprietà del CEO0.5%
Durata media del management3.3yrs
Durata media del Consiglio di amministrazione3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Sep 13

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics (NASDAQ:BIOR) said on Tuesday the United States Patent and Trademark Office had issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The patent is for methods for using an ingestible device to treat a disease or condition in a patient using jet delivery of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist formulation to the small intestine. GLP-1 receptor agonists are a class of drug approved for type 2 diabetes and weight loss.
Seeking Alpha • Aug 17

Biora Therapeutics: Checking In On The Transformation

Today, we take our first look at the rebranded/refocused Biora Therapeutics in 2022. When we last looked at this company, it was still transitioning from being a genetic testing company to being a developmental drug company. How is the transformation working out to date?  An investment analysis follows in the paragraphs below. Everyone thinks of changing the world, but no one thinks of changing himself." - Leo Tolstoy Today, we put Biora Therapeutics (BIOR) in the spotlight for the first time this year. When we last looked at this entity in the fourth quarter of last year, it was still transitioning from being an entity called Progenity (PROG). The company was in the middle of transforming from its focus as a genetic testing company to being a company focused on developing its drug candidates. Second quarter results just hit the wires this week. Therefore, it seems an opportune time to peak back in on this small cap concern and check in on how its transformation is proceeding. An analysis follows below. Seeking Alpha Company Overview: August Company Presentation The refocused Biora Therapeutics is still based in San Diego. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the GI tract to enhance the treatment of inflammatory bowel diseases. Leadership believe this approach has plenty of potential targets, including holding great promise to more effectively treat Ulcerative Colitis, a large indication. It also is targeting IBD. According to management on its last earnings conference call. Annual global sales for UC drugs are estimated to be approximately $7 billion and the inflammatory bowel disease or IBD space overall is about $19 billion globally. " August Company Presentation August Company Presentation Here is the current development plan for the most advanced candidate in this developmental area, PGN - 600, which is combination of Biora's device and their proprietary formulation of tofacitinib. August Company Presentation The company is also focused on an oral delivery approach via ingestible capsules as an alternative to intramuscular injectable vaccines. This method could eventually see use for proteins as well as monoclonal antibodies. August Company Presentation The replacement of needle injection via an easy to take oral capsule could yield more effective results in a variety of disease areas. The company has a research collaboration with Ionis Pharmaceuticals (IONS) in these initial efforts. Preclinical activities should run into the third quarter of 2023, and are scheduled to start early stage clinical activities by the end of that year. The company estimates the area of the diabetes market it is targeting to be well over $20 billion by 2025. August Company Presentation Management believes the management of diabetes could be vastly improved to name one large target area. August Company Presentation With two core developmental focus areas, the company has numerous candidates in the pipeline. The company's portfolio has numerous patents around the company's intellectual property. That said, its candidates all in the very early stages of the long developmental lifecycle as can be seen above. August Company Presentation
Seeking Alpha • Aug 10

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics (NASDAQ:BIOR), a biotech focused on oral biotherapeutics, surged ~30% on Wednesday to record the highest intraday gain since November after the company announced promising topline data from a study for its targeted therapeutics platform. The recently completed PM-602 was designed to evaluate the Drug Delivery System Capsule (DDS) in patients with ulcerative colitis in a fasted state. According to the data, the device was well tolerated and performed as expected in all UC patients after a single oral ingestion. Accurately identifying the entry into the colon, the device released a saline solution payload that included radioisotopes, leading to distribution across the entire colon in all seven patients. Biora (BIOR) plans to release further information on the study after completing the analysis and intends to submit data for publication. “These human studies are key steps in advancing toward our PGN-600 clinical program, and they also demonstrate the potential of the platform for localized delivery of other drugs,” Chief Executive Adi Mohanty noted. Biora (BIOR) was previously identified as Progenity.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Adi Mohanty rispetto agli utili di Biora Therapeutics?
DataCompenso totaleStipendioUtili della società
Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$111m

Dec 31 2023US$3mUS$574k

-US$124m

Sep 30 2023n/an/a

-US$122m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$4mUS$550k

-US$49m

Sep 30 2022n/an/a

-US$118m

Jun 30 2022n/an/a

-US$140m

Mar 31 2022n/an/a

-US$176m

Dec 31 2021US$10mUS$63k

-US$179m

Compensazione vs Mercato: La retribuzione totale di Adi ($USD 3.14M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.55K ).

Compensazione vs guadagni: La retribuzione di Adi è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Adi Mohanty (57 yo)

3.5yrs
Mandato
US$3,139,017
Compensazione

Mr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. Mr. Mohanty founded En...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Aditya Mohanty
CEO & Director3.5yrsUS$3.14m0.52%
$ 3.1k
Clarke Neumann
Senior VP10.7yrsUS$1.53m0.18%
$ 1.1k
Kevin Howe
Senior VP of Strategic Operationsno dataNessun datoNessun dato
Paul Shabram
Head of Technical Operations3.1yrsNessun datoNessun dato
James Knight
Head of Business Development1.3yrsNessun datoNessun dato
3.3yrs
Durata media

Gestione esperta: Il team dirigenziale di BIOR.Q è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Aditya Mohanty
CEO & Director3.5yrsUS$3.14m0.52%
$ 3.1k
Brian Gordon Feagan
Member of Inflammatory Bowel Disease Clinical Advisory Boardno dataNessun datoNessun dato
Brian Kotzin
Independent Director5.9yrsUS$185.11k0.041%
$ 245.8
Geert D'Haens
Member of Inflammatory Bowel Disease Clinical Advisory Board3.9yrsNessun datoNessun dato
Bruce Sands
Chairman of Inflammatory Bowel Disease Clinical Advisory Board3.9yrsNessun datoNessun dato
Jeffrey Alter
Independent Chairman6.3yrsUS$208.11k0.043%
$ 256.5
Lynne Powell
Independent Director6.3yrsUS$163.11k0.041%
$ 245.7
Severine Vermeire
Member of Inflammatory Bowel Disease Clinical Advisory Board3.9yrsNessun datoNessun dato
Jill Howe
Independent Director3.5yrsUS$180.11k0.040%
$ 241.1
3.9yrs
Durata media
57yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BIOR.Q sono considerati esperti (durata media dell'incarico 3.9 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/05/27 04:22
Prezzo dell'azione a fine giornata2025/05/27 00:00
Utili2024/09/30
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Biora Therapeutics, Inc. è coperta da 5 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Catherine Ramsey SchulteBaird
Steven MahPiper Sandler Companies
Andrew CooperRaymond James & Associates